View Report
January 12, 2026
Measured Result 5.85 mg / 5.97 mg TB-500 117% / BPC-157 119.4% of label claim
Batch #GATBBPC12
Peptide Hubs
Peptide Hubs
Latest Laboratory Result 5.85 mg / 5.97 mg January 12, 2026 · TB-500 117% / BPC-157 119.4% of label claim View
You will save $30.00
TB 500/BPC 157
Product Information Compound Details
Active Formula TB 500 / BPC 157 Blend
10 mg/vialThymosin Beta 4 (TB-500 fragment) 5 mg
Body Protection Compound 157 5 mg
Total Strength 10 mg/vial
Package 1 Vial 2 mL vial
Form Lyophilized Powder
Vial Size 2 mL Vial
Drug Class Research Peptide
Manufacturer Peptide Hubs
$45.00
$75.00
Shipping :
International
U.S. Domestic
Product Overview
TB 500/BPC 157 by Peptide Hubs
TB 500/BPC 157 is a lyophilized research peptide blend manufactured by Peptide Hubs and supplied in a 2 mL vial containing 5 mg of Thymosin Beta 4 (TB-500 fragment) and 5 mg of BPC 157.
TB 500 and BPC 157 Peptide Blend
TB 500/BPC 157 combines two synthetic research peptides with complementary mechanisms in tissue repair and recovery research. Thymosin Beta 4 is a naturally occurring actin-sequestering protein, and its TB-500 fragment corresponds to the active LKKTETQ actin-binding region. BPC 157 is a stable gastric pentadecapeptide with a sequence derived from human gastric juice protein.
In preclinical research, Thymosin Beta 4 has been studied for its roles in cell migration, tissue repair, and angiogenesis, while BPC 157 has been investigated for cytoprotective and anti-inflammatory properties. Both peptides are commonly referenced together in non-medical bodybuilding contexts as a recovery stack, though neither is FDA-approved for any human indication.
The FDA has evaluated both TB-500 and BPC-157 as bulk drug substances for compounding and determined that the evaluation criteria weigh against placing them on the 503A Bulks List due to insufficient characterization, potential immunogenicity, and limited safety data. In July 2026, an FDA advisory committee voted to recommend inclusion of both peptides on the 503A list, though this vote is advisory and does not constitute FDA approval.
Key Benefits of TB 500/BPC 157
- Combines actin-binding TB-500 fragment with cytoprotective BPC 157
- Studied in preclinical models for tissue repair and recovery applications
- Complementary mechanisms covering cell migration and angiogenesis research
- Lyophilized powder format for extended storage stability
- Supplied in a 2 mL vial suitable for laboratory reconstitution
Format
Lyophilized Powder
TB 500/BPC 157 is supplied as a lyophilized powder, a freeze-dried format designed to preserve peptide integrity during storage. Reconstitution is required before research use.
Product Profile
Thymosin Beta 4 & BPC 157 Profile
This product combines two research peptides with distinct but complementary mechanisms. Thymosin Beta 4 (TB-500 fragment) acts on actin sequestration and cell migration, while BPC 157 has been studied for cytoprotective and angiogenic properties.
TB-500 and BPC 157 Research Peptides
The TB-500 component is a synthetic seven-amino-acid fragment (Ac-LKKTETQ) corresponding to residues 17-23 of human thymosin beta-4. This region contains the actin-binding site understood to be responsible for the parent protein's role in cell migration and tissue repair.
BPC 157 is a stable gastric pentadecapeptide with the sequence GEPPPGKPADDAGLV. Preclinical research has explored its effects on angiogenesis, inflammation, and tissue protection, with proposed mechanisms involving VEGF signaling and focal adhesion kinase pathways.
Unlike anabolic-androgenic steroids or growth hormone secretagogues, neither peptide is associated with muscle-building or hormonal pathways. Their research profile centers on tissue repair mechanisms rather than anabolic or performance-enhancement effects.
Defining Characteristic
Complementary Repair Mechanism Blend
TB 500/BPC 157 combines the actin-binding and cell-migration properties of the TB-500 fragment with the cytoprotective and angiogenic research profile of BPC 157. The two peptides have distinct structures and mechanisms, making this blend a dual-pathway research format.
TB 500/BPC 157 vs Other Peptide Hubs Preparations
Peptide Hubs offers TB 500/BPC 157 as a combined lyophilized powder, as well as each peptide separately as TB 500 5 mg and BPC 157 5 mg. For research involving GH pathways, CJC-1295/Ipamorelin 10 mg represents a GHRH analogue and ghrelin agonist combination.
Laboratory Testing
TB 500/BPC 157 Lab Reports
Published laboratory reports for TB 500/BPC 157 by Peptide Hubs are shown below with the test date, measured content for each component, and percentage of the product's 5 mg per-peptide label claim.
View Report
View Report
September 29, 2025
Measured Result 5.34 mg / 5.61 mg TB-500 106.8% / BPC-157 112.2% of label claim
Batch #TBBPCGA8
View Report
April 22, 2025
Measured Result 5.40 mg / 5.71 mg TB-500 108% / BPC-157 114.2% of label claim
Laboratory results apply to the specific tested sample represented in each published report and should not be interpreted as a measurement of every vial or production batch.
Dosage & Usage
TB 500/BPC 157 Dosage & Usage
The information below is provided for educational reference only. Neither Thymosin Beta 4 nor BPC 157 is FDA-approved for any human indication. Any non-medical use falls outside approved indications and should not be undertaken without appropriate supervision.
Typical Dosage Ranges
In non-medical research and bodybuilding contexts, TB 500 and BPC 157 are commonly referenced with a loading phase followed by maintenance. TB-500 is typically referenced at 2–5 mg per week during loading, while BPC-157 is commonly referenced at 250–500 mcg per day. When using a combined blend such as TB 500/BPC 157, these component doses correspond to a total peptide blend draw based on the vial's 1:1 ratio.
| Use Case | Common Reference Range | Frequency |
|---|---|---|
| TB-500 loading (non-medical) | 2–5 mg / week | 2–3 administrations per week |
| TB-500 maintenance (non-medical) | 2–2.5 mg / week | 1 administration per week |
| BPC-157 (non-medical) | 250–500 mcg / day | Once daily |
| Combined blend research | Protocol-dependent | Per research design |
Note: Clinical evidence for TB-500 and BPC-157 in humans is extremely limited. Dosing protocols referenced in non-medical contexts are not supported by controlled human trials.
Stacking & Cycle Considerations
In non-medical research contexts, TB 500 and BPC 157 are most commonly used together as a recovery stack due to their complementary mechanisms. A combination product containing both peptides in a 1:1 ratio is available as TB 500/BPC 157 10 mg. Cycle lengths referenced in research contexts typically range from 4 to 8 weeks, with washout periods of 2 to 4 weeks before repeating.
Some protocols reference tapering TB-500 before BPC-157 due to TB-500's longer biological half-life and tissue accumulation.
Managing Side Effects
Community-reported side effects include injection site irritation, headache, nausea, and lightheadedness. The FDA has noted theoretical concerns about immunogenicity and aggregation when peptides are administered via injectable routes. Both peptides have pro-angiogenic properties, raising theoretical concerns about use in individuals with active malignancy.
Post-Cycle Therapy
Post-cycle therapy is not applicable to TB 500/BPC 157, as neither peptide suppresses endogenous testosterone production or alters the hypothalamic-pituitary-gonadal axis. Both act on tissue repair and cell migration mechanisms without direct hormonal effects.
Important
Individual Response Varies
Research peptide protocols should be based on published study designs and appropriate institutional oversight. The information above is for educational reference and does not constitute medical advice or a recommendation for use.
Safety & Information
Thymosin Beta 4 & BPC 157 Safety Information
Neither Thymosin Beta 4 (TB-500) nor BPC 157 is FDA-approved for any human indication. The FDA has evaluated both as bulk drug substances and determined that the criteria weigh against placing them on the 503A compounding list.
Important Safety Information
The FDA has noted concerns about immunogenicity and aggregation when peptides such as TB-500 and BPC-157 are administered via injectable routes. Inconsistent naming conventions for these substances also introduce risks because of the inability to determine which specific bulk drug substance a particular reference standard is referencing.
There are no published Phase 2 or Phase 3 human trials testing subcutaneous TB-500 for musculoskeletal repair. For BPC-157, only three uncontrolled pilot studies with a combined sample size of 30 participants have been reported.
Important
Non-Medical Use
TB 500/BPC 157 is not approved for human use in the United States. Non-medical use of research peptides falls outside approved indications and carries unknown risks.
Potential Adverse Effects
Community-reported side effects include injection site irritation, headache, nausea, and lightheadedness. In Phase 1 human trials of recombinant thymosin beta-4 administered intravenously, adverse events were mild to moderate and not significantly different from placebo.
The pro-angiogenic properties of both thymosin beta-4 and BPC-157 raise theoretical concerns regarding use in individuals who may harbor subclinical or undiagnosed malignancies, as angiogenesis is a hallmark of tumor growth.
Conditions Requiring Medical Evaluation
TB-500 and BPC-157 have not been evaluated for use in pregnancy, breastfeeding, or pediatric populations. Individuals with active malignancy or a history of cancer should exercise particular caution given the pro-angiogenic properties of both peptides. Competitive athletes should note that TB-500 and BPC-157 are prohibited by the World Anti-Doping Agency.
Monitoring During Research Use
Research use of TB-500 and BPC-157 should be conducted under appropriate institutional oversight with defined protocols for monitoring and adverse event reporting. Clinical monitoring parameters for these peptides have not been established in FDA-reviewed literature.
Product Care
Storage & Handling
Keep the vial securely stored and protected from conditions that could compromise the product. Inspect the vial before use and do not use a product that appears damaged or compromised.
Shipping & Authenticity
Shipping & Product Authenticity
TB 500/BPC 157 is supplied through the Peptide Hubs distribution chain and shipped with discreet, privacy-focused handling.
USA Domestic 3–5 business days
International 10–15 business days
Order Processing 24–48 business hours
Tracking Provided after dispatch
Direct Supply
Discreet Delivery & Original Packaging
The outer shipping package remains discreet, with privacy-focused handling. Products are supplied through the official Peptide Hubs distribution chain.
What to Expect
- Orders are processed after payment confirmation
- USA Domestic shipping is typically faster when local stock is selected
- International orders include tracking, though update frequency may vary by destination
- Multiple warehouses may result in separate shipments when applicable
Authenticity Verification
To verify your TB 500/BPC 157 product, use the security code on the vial label and cross-check it on the Peptide Hubs official site. Original packaging and batch-linked laboratory documentation help reinforce product legitimacy.
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Storage
TB 500/BPC 157 Storage
Proper storage conditions help preserve peptide integrity and stability throughout the product's shelf life.
Recommended Conditions
Store the lyophilized powder refrigerated at 2–8°C and protected from light. Keep the vial in its original packaging until use.
After reconstitution, store the solution refrigerated at 2–8°C and use within 28 days. Do not freeze reconstituted solution.
Reconstituted TB 500/BPC 157 solution should be clear and colorless. Cloudiness or visible particulates indicate degradation and the vial should be discarded.
Quick Reference
Do & Don't
- Do store lyophilized powder refrigerated at 2–8°C
- Do protect from light and moisture
- Do use reconstituted solution within 28 days
- Don't freeze reconstituted solution
- Don't expose to excessive heat
- Don't use if solution appears cloudy or discolored
Frequently Asked Questions
TB 500/BPC 157 FAQ
Answers to common questions about TB 500/BPC 157, the Thymosin Beta 4 and BPC 157 peptides, laboratory testing, and research applications.
What is TB 500/BPC 157 used for?
TB 500/BPC 157 is a research peptide blend supplied as lyophilized powder. Thymosin Beta 4 and BPC 157 have been studied in preclinical models for tissue repair and recovery applications. In non-medical bodybuilding contexts, the blend is commonly referenced as a recovery stack, though such use falls outside approved indications.
How often should TB 500/BPC 157 be injected?
Non-medical protocols commonly reference TB-500 at 2–5 mg per week during loading and BPC-157 at 250–500 mcg per day. When using a combined blend, the total draw is calculated based on the vial's 1:1 ratio of each peptide.
Does TB 500/BPC 157 require PCT?
No. Post-cycle therapy is not applicable to TB 500/BPC 157, as neither peptide suppresses endogenous testosterone production or alters hormonal axes. Both act on tissue repair mechanisms without direct hormonal effects.
What does Thymosin Beta 4 do?
Thymosin Beta 4 is a naturally occurring actin-sequestering protein that plays roles in cell migration, tissue repair, and angiogenesis. The TB-500 fragment corresponds to the actin-binding region (LKKTETQ) of the full-length protein.
How long does TB 500/BPC 157 take to work?
In preclinical studies, effects on tissue repair have been observed over days to weeks depending on the model. No human clinical data exist to establish an onset timeline for either peptide.
Is TB 500/BPC 157 the best recovery stack?
There is no single recovery stack that is universally best. TB 500 and BPC 157 have complementary mechanisms and are commonly studied together in research contexts. Individual TB 500 5 mg and BPC 157 5 mg preparations are also available for separate research applications.
What is the difference between TB 500 and BPC 157?
TB 500 and BPC 157 have different structures and mechanisms. TB 500 is a fragment of thymosin beta-4 that acts on actin sequestration and cell migration, while BPC 157 is a pentadecapeptide studied for cytoprotective and angiogenic properties.
What is the difference between TB 500/BPC 157 and TB 500 alone?
TB 500/BPC 157 combines both peptides in a 1:1 ratio, while TB 500 alone contains only the Thymosin Beta 4 fragment. The blend format allows research on the combined effects of both peptides, which have complementary mechanisms in tissue repair research.
Is 10 mg a lot of TB 500/BPC 157?
A 10 mg vial of TB 500/BPC 157 provides 5 mg of each peptide. At commonly referenced non-medical doses, this provides approximately 1–2 weeks of material for TB-500 and up to several weeks for BPC-157 depending on the protocol.
What strength is TB 500/BPC 157?
TB 500/BPC 157 by Peptide Hubs is labeled at 10 mg total per vial, comprising 5 mg of Thymosin Beta 4 (TB-500 fragment) and 5 mg of BPC 157. The product is supplied as lyophilized powder in a 2 mL vial.
Is TB 500/BPC 157 lab tested?
Yes. The latest published laboratory report dated January 12, 2026 measured TB 500/BPC 157 at 5.85 mg TB-500 and 5.97 mg BPC-157, equivalent to 117% and 119.4% of the respective 5 mg label claims. Additional reports from September 2025 and April 2025 are also available in the Lab Reports tab.
How should TB 500/BPC 157 be reconstituted?
Lyophilized peptides are typically reconstituted with bacteriostatic water or sterile saline. Bacteriostatic Water is commonly used for peptide reconstitution to maintain sterility over multiple draws. For a 10 mg total vial, adding 2 mL of diluent yields a concentration of 5 mg per mL total peptide.
Related Offers
Lab Tested
Domestic & International
-40% OFF
Peptide Hubs
Product Information Compound Details
Active Substance Pentadecapeptide BPC 157 (Body Protection Compound)
5 mg/vialStrength 5 mg/vial
Package 1 Vial
Form Lyophilized Powder
Vial Size 2 mL Vial
Drug Class Research Peptide
Manufacturer Peptide Hubs
$22.80
$38.00
Lab Tested
Domestic & International
-40% OFF
Peptide Hubs
Product Information Compound Details
Active Substance Bremelanotide Melanocortin receptor agonist
10 mg/vialStrength 10 mg/vial
Amount 1 Vial Lyophilized powder
Form Lyophilized Powder
Vial Size 2 mL Vial
Drug Class Research Peptide
Manufacturer Peptide Hubs
$24.00
$40.00